Astrazeneca PLC (NYSE:AZN) stock is expected to deviate a maximum of $1.38 from the average target price of $35.55 for the short term period. 3 Street Experts have initiated coverage on the stock with the most promising target being $37 and the most muted being $34.
Other Equity analysts have also commented on the company shares. Leerink Swann maintains its view on Astrazeneca PLC (NYSE:AZN) according to the research report released by the firm to its investors. The shares have now been rated Market Perform by the stock experts at the ratings house. Leerink Swann lowers the price target from $38 per share to $34 per share on Astrazeneca PLC. The rating by the firm was issued on May 2, 2016.
Astrazeneca PLC (NYSE:AZN): stock turned positive on Thursday. Though the stock opened at $29.12, the bulls momentum made the stock top out at $29.3099 level for the day. The stock recorded a low of $28.8 and closed the trading day at $29.29, in the green by 2.06%. The total traded volume for the day was 4,196,994. The stock had closed at $28.7 in the previous days trading.
The company shares have dropped -12.85% from its 1 Year high price. On Dec 1, 2015, the shares registered one year high at $34.88 and the one year low was seen on Jun 16, 2016. The 50-Day Moving Average price is $28.77 and the 200 Day Moving Average price is recorded at $30.09.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).